中国与国际“寻常型天疱疮诊断与治疗专家建议”解读

Comparison of Recommendations for Diagnosis and Management of Pemphigus Vulgaris between China and International Expert Groups

寻常型天疱疮是一类严重威胁人类健康、具有潜在致死性的自身免疫性大疱性皮肤病。糖皮质激素仍是其主要治疗手段,利妥昔单抗的使用渐渐显示出其治疗的优越性,但如何更为规范、合理、安全的治疗天疱疮,仍是目前临床医生关注的重点。目前许多国家已经制定了各国关于天疱疮诊治的专家共识或指南,中国也分别于2016年和2020年发布了两版寻常型天疱疮诊疗的专家建议。2020年,一个包括多国专家的小组发布了天疱疮诊疗的国际专家建议,以克服不同国家间指南的差异,试图制定在世界范围内相对普遍适用的天疱疮诊疗指南。本文主要对2020年版中国寻常型天疱疮诊断和治疗专家建议和2020年版国际专家小组天疱疮诊治的共识进行解读和比较,以呈现两者之间的差异,分析其背后可能的原因,更好的指导临床。

Pemphigus vulgaris is a potentially fatal autoimmune bullous skin disease.At present,many countries have formulated expert recommendations on the diagnosis and treatment of pemphigus.China has also issued two versions of expert recommendations on the diagnosis and treatment of pemphigus vulgaris in 2016 and 2020.In 2020,a group of experts from many countries also issued international expert recommendations for pemphigus diagnosis and treatment,in order to overcame the differences in guidelines among different countries and formulate universal consensus for the treatment of pemphigus worldwide.This article mainly compares the latest version of China's expert recommendations for pemphigus vulgaris diagnosis and treatment with the recommendations of an in ternational panel of experts,in order to present the differences between the two and analyze the possible reasons for them.